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ABSTRACT

A method for preparing nonradioactive microspheres
adapted for radiation synovectomy of arthritic joints in
a mammal involves forming the microspheres by dop
ing a biodegradable glass material which may be lithium
or potassium silicate, lithium or potassium aluminosili
cate, lithium or potassium aluminoborate, lithium or
potassium germanate or lithium or potassium aluminogermanate with an isotope which may be samarium,
holmium, erbium, dysprosium, rhemium or yttrium so
that the isotope is chemcially dissolved in and distrib
uted uniformly throughout the glass material. The
doped glass material is then treated with an acid wash to
produce a thin layer on the surface thereof and heat
treated to improve the chemical durability of the glass
material by rendering the solubility of the layer lower
than that of the underlying glass material.
13 Claims, 2 Drawing Sheets
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the surgeon. Some of these are: 1) cost, 2) the risk of
C O M PO Sm O N AND METHOD FOR RADIATION
infection, 3) the fact that the implants may come loose
SYNOVECTOMY OF ARTHRITIC JOINTS
and be painful, and 4) the fact that the implant may
break with unusual use.
This is a division of application Ser. No. 150,154, filed 5
Chemical and radioisotope synovectomy (synoviorJan. 29, 1988, now U.S. Pat. No. 4,889,707.
thesis) constitutes an effective alternative to operative
therapy . The advantages of synoviorthesis are: 1) sim
BACKGROUND OF THE INVENTION
ple techniques employed in their use, 2) decreased or no
This invention relates to radiation synovectomy for
hospitalization, 3) lower costs, 4) early and easier mobi
arthritic joints and, more particularly, to novel biode 10 lization of the patient, and 5) a surgical synovectomy
gradable and biologically compatible glass micro
remains an alternative treatment should the synovior
spheres or beads and their use in carrying out radiation
thesis not work.
synovectomy of arthritic joints.
In general, the results of radioisotope synoviorthesis
Current medical management of rheumatoid arthritis
appear to be superior to those attained with chemical
includes patient education, appropriate rest and physi 15 synovectomy. (Menkes, C. J., et al. La Synoviorthese a
cal therapy, and the use of anti-inflammatory drugs for
L’acide Osmique Chez L’hemophilie, Rev. Rhum.
relief of pain and inflammation. Ruddy, S., The Man
40:255, 1973; Oka, M., et al., The Fate and Distribution
agement of Rheumatoid Arthritis. Textbook of Rheu
of Intra-Articularly Injected Osmium Tetraoxide, Acta
matology, 2nd ed., W. B. Saunders Co. Philadelphia,
Rheum. Scand., 16:271, 1970; Delbarre, F., et al., La
1985, p. 979. Patients who do not respond to these mo 20 Synoviorthese par les Radio-Isotopes a la Main et au
dalities may require therapy with anti-malarial agents
Poignet, Rev. Rhum., 40:205, 1973). Some chemical
such as hydroxychloroquine (Bell, C.L., Hydroxychlo
agents that have been used are thio-tepa (Flatt, A.E.,
roquine Sulfate in Rheumatoid Arthritis: Long-Term
Intra-Articular Thio-Tepa in Rheumatoid Disease of
Response Rate and Predictive Parameters, American
the Hands, Rheumatism, 18:70, 1962; Fearnley, M.D.,
Journal of Medicine, 75:46, 1983) or remission inducing 25 Intra-Articular Thio-Tepa Therapy in Rheumatoid Ar
agents including gold salts (Empire Rheumatism Coun
thritis, Ann. Phys. Med., 7:294, 1963; Zuckner, J., et al.,
cil, Gold Therapy in Rheumatoid Arthritis: Final Re
Evaluation of Intra-Articular Thio-Tepa in Rheumatoid
port of a Multicentre Controlled Trial, Ann. Rheum.
Arthritis, Ann. Rheum. Dis., 25:178, 1966; Gross, D.,
Dis. 20:315, 1961), penicillamine (Multicentre Trial
Chemische Synovektomie mit Senfgas bei Primar ChroGroup: Controlled Trial of d(—) Penicillamine in Se 30 nischer Polyarthritis, Z. Rheumforsch, 22:456, 1963;
vere Rheumatoid Arthritis, Lancet, 1:275, 1973), or
Mondragon Kalb, M., Thiotepa en al Tratamiento de la
azathioprine (Abel, T. et al., Long-Term Effects of
Arthritis Rhumatoide, Medicina, 15:82, 1965), osmic
Azathioprine in Rheumatoid Arthritis, Arthritis
acid (Menkes, C.J., et al., La Synoviorthese a L’acide
Rheum. 21:539, 1978). Despite the efficacy of these
Osmique Chez L’hemophilie, Rev. Rhum., 40:255, 1973;
drugs, patient response is variable and improvement 35 Oka, M., et al., The Fate and Distribution of Intramay not occur until treatment has extended for three to
Articularly Injected Osmium Tetraoxide, Acta Rheum.
six months. When a few joints remain swollen and pain
Scand., 16:271, 1970; Von Reis, G., et al., Intra-Articu
ful and interfere with the patient’s progress, intra-articular Injections of Osmic Acid in Painful Joint Affections,
lar instillation of corticosteroids may be used as an ad
Acta Med. Scand. Suppl., 259: 27, 1951; Berglof, F.E.,
junct to systemic therapy. This local remedy, however, 40 Further Studies on the Use of Osmic Acid in the Treat
may be ineffective or may last only a few days (Owen,
ment of Arthritis, Acta Rheum. Scand., 10:92, 1964;
D.S., Aspiration and Injection of Joints and Soft Tis
Martio, J., et al., Intra-Articular Osmic Acid in Juvenile
sues, Textbook of Rheumatology, supra, p. 546).
Rheumatoid Arthritis, Scand. J. Rheumatol, 1:5, 1972;
Surgery may be used in several different ways to help
Brattstrom, H., et al., Kombinierte Chemische und Op
the patient with rheumatoid arthritis. Surgery can help 45 erative Synovektomie es Kniegelenks, Orthapade, 2:73,
relieve pain, it can prevent further deformity and loss of
1973; Jakubowski, S., et al., Indikatronen zur Synovek
function, or at least allay these problems, and when
tomie bei pcP, orthopade, 2:6, 1973), varicoid (Tillman,
destruction has occurred, reconstructive procedures
K., Chemische Synovektomie, Orthopade, 2:10, 1973)
can return function to a part or a limb. Sledge, C.B.,
and gold (Delbarre, F., et al., supra). Radioactive sub
Introduction to the Surgical Management of Arthritis, 50 stances include Gold-198, Yttrium-90 citrate, YttriumTextbook of Rheumatology, supra, p. 1787.,
90 resin, Rhenium-186, Erbium-169, Yttrium-90 ferric
Most of the operations done on rheumatoid patients
hydroxide, Radium-224 and Phosphorus-32 chromic
relieve pain. Fusions of joints, total joint replacement
phosphate (Sledge, C.B., supra).
and synovectomy are examples of procedures that sig
Beta-emitting radionuclides are considered the most
nificantly reduce pain. Conaty (Conaty, J.P., Surgery of 55 useful for radiotherapeutic applications because of the
the Hip and Knee in Patients with Rheumatoid Arthri
moderate linear energy transfer (LET) of the ionizing
tis, Journal of Bone and Joint Surgery, 55(A):301, 1973)
particle (electron) and its intermediate range (typically
states that in rheumatoid arthritis, synovectomy was the
several millimeters in tissue). In contrast, gamma rays
most successful procedure for preserving motion of a
deliver dosage at lower levels over much greater dis
joint, except for total joint arthroplasty.*This proce 60 tances, thus hampering the localization of the dose and
dure, then, is preventive. Even so, eventually the syno
diluting its effect. Alpha particles represent the other
vium regenerates and the process continues (Patzakis,
extreme; they deliver very high LET dosage, but have
M.J. et al., A Visual, Histological, and Enzymatic Study
an extremely limited range and must, therefore, be in
of Regenerating Rheumatoid Synovium in the Synointimate contact with the cells of the tissue to be treated.
vectomized Knee, Journal of Bone and Joint Surgery, 65 In addition, alpha emitters are generally heavy metals,
55(A):287, 1973). Total joint surgery will relieve any or
which limits the possible chemistry and presents undue
all of the aforementioned disabilities, but brings with it
hazards from leakage of radionuclide from the area to
other problems that must be taken into consideration by
be treated.
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It is fortuitous that beta emitters, the most useful
synoviorthesis has a role in the treatment of inflamma
radiotherapeutic radionuclides, are also the ones most
tory synovitis.
copiously produced by neutron capture in nuclear reac
In our copending, coassigned application for U.S.
tors, the most powerful sources of radioisotopes. Reac
patent Ser. No. 673,123, filed Nov. 19, 1984,now U.S.
tor-produced isotopes number in the thousands, giving 5 Pat. No. 4,789,501 we disclose novel microspheres for
researchers a wide choice of isotopes of various halfuse in the radiation therapy of liver cancer and other
lives, beta energies, gamma emissions, and chemical
cancerous or tumor bearing tissue. Such microspheres
properties. Gamma emissions, while not as useful for
have not, however, been used or suggested for use in
therapy as beta emissions, play an important role in that
radiation
synovectomy of arthritic joints and may not
10
they permit the distribution of radioisotope in the body
be
suitable
for use in radiation synovectomy by reason
to be observed using an Anger gamma ray camera or
of
the
radionuclides
incorporated therein having rela
single photon computed tomography (SPECT) instru
tively long physical half-lives.
ment. This permits direct observation and, to some
There is a continuing need, therefore, for improved
extent, quantification of radionuclide leakage from an
organ or a joint and also provides positive verification 15 microspheres and methods for radiation synovectomy
of arthritic joints.
of the potency of joint injection and distribution of the
radionuclide in the research animal.
SUMMARY OF THE INVENTION
Treatment of the different depths of diseased syno
Among the several objects of the invention may be
vium in joints of disparate size, such as the finger joints
and the knee, requires isotopes of different average beta 20 noted the provision of novel microspheres for use in
range. It is important to achieve a “kill” of sufficient
radiation synovectomy of arthritic joints; the provision
depth to be efficacious without causing significant ne
of such microspheres containing beta emitting radioiso
crosis of overlying normal tissues.
topes which have a moderately abundant low energy
The effectiveness of a radioisotope depends upon the
gamma photon that is in the energy range used for
fact that it gives off beta radiation which kills tissue 25 nuclear medicine imaging; the provision of such micro
along with the fact that it gives off no alpha and little
spheres which are biodegradable and advantageously
gamma radiation. The latter type of radiation penetrates
gradually dissolve after they are no longer radioactive;
too far, affecting tissues adversely, whereas beta radia
the provision of such microspheres which are prepared
tion has a short penetration distance, varying in millime
30 in a nonradioactive form and may then be subjected to
ters for each radioisotope. Radioisotopes also have dif
an effective amount of neutron irradiation to produce
ferent half-lives, some being far too long or too short for
microspheres containing the desired beta emitting radi
any practical use. These factors, then, have to be con
oisotope; and the provision of methods for carrying out
sidered in the application of a radioisotope for synoviorradiation synovectomy of arthritic joints and for pre
thesis.
35 paring biodegradable microspheres for use in radiation
Sledge et al. (Treatment of Rheumatoid Synovitis of
synovectomy. Other objects and features will be in part
the Knee with Intra-Articular Injection of Dysprosiumapparent and in part pointed out hereinafter.
165 Ferric Hydroxide Macroaggregates, Arthritis and
Briefly, the present invention is directed to novel
Rheumatism, 29(2): 153, 1986) have used macroaggre
gates of ferric hydroxide (FHMA) combined with dys- 40 radioactive microspheres useful for radiation synovec
tomy of arthritic joints. These radioactive microspheres
prosium-165. This compound does present the problem
comprise a biodegradable or biologically compatible
of some leakage to local lymph nodes and other tissues.
Also, dyprosium-165 has a half-life of 2.3 hours, making
glass material containing a beta radiation emitting radio
it necessary for the patient to be close to a nuclear reac
isotope chemically dissolved therein. In a preferred
tor, severely limiting the use of this radioisotope. Even 45 embodiment, such microspheres have been subjected to
with these drawbacks, the clinical results were note
an acid wash to produce a sparingly soluble coating on
worthy, as 80% of patients treated for chronic synovitis
their outer surface so that the microspheres gradually
of the knee with dysprosium-165-FHMA were im
dissolve after they are no longer radioactive.
proved at one year, and nearly 90% of patients with
Another aspect of the invention is the provision of
Stage 1 roentgenographic changes had excellent, good, 50 novel microspheres which are initially nonradioactive
or fair results (Sledge, et al., Intra-Articular Radiation
and which, upon being subjected to an effective amount
Synovectomy, Clinical Orthopaedics and Related Re
of neutron irradiation, will produce a beta radiation
search, 182:37, 1984). These results and the results of
emitting radioisotope thereby rendering the micro
others (Boerbooms, A.M., et al., Radio-Synovectomy in
Chronic Synovitis of the Knee Joint in Patients with 55 spheres suitable for use in radiation synovectomy of
arthritic joints while avoiding the handling of radioac
Rheumatoid Arthritis, European Journal of Nuclear
tive elements during initial production of the micro
Medicine, 10:446, 1985; Multicentre Trial Group: Intraspheres.
Articular Radioactive Yttrium and Triamcinolone HexA still further aspect of the invention resides in the
acetonide: An Inconclusive Trial, Ann. Rheum. Dis.,
43:620, 1984; Kyle, V., et al., Yttrium-90 Therapy and 60 provisions of novel methods for carrying out radiation
synovectomy of arthritic joints utilizing the novel radi
99m~Yc Pertechnetate Knee Uptake Measurements in the
oactive microspheres of the invention.
Management of Rheumatoid Arthritis, Annals of the
Rheumatic Diseases, 42:132, 1983; Rosenthall, L., Use
BRIEF DESCRIPTION OF THE DRAWINGS
of Radiocolloids for Intra-Articular Therapy for Syno
vitis, In Therapy in Nuclear Medicine, Grune and Strat 65
FIGS. 1 and 2 are graphs showing the dissolution
ton, Inc., New York, 1978, p. 147; Spooren, P. et al.,
(weight loss in mg/cm2) of two different glass composi
Synovectomy of the Knee with 90-Y, European Journal
tions of the invention in deionized water at 37° C. as a
of Nuclear Medicine, 10:441, 1985) show that radiation
function of time.
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tron and resonance neutron cross sections of 61.2 and
DESCRIPTION OF THE PREFERRED
670 bams, respectively. It decays with a 26.83 hour
EMBODIMENTS
half-life by emission of 1.855 MeV (51%) and 1.776
In accordance with the present invention, it has now
MeV (48%) maximum energy beta particles with a
been found that certain novel radioactive microspheres 5 maximum range in water of about 8.0 mm and an aver
may be advantageously employed in radiation synovec
age range of about 2 mm. Since dysprosium-165 emits a
tomy of arthritic joints while substantially avoiding
beta particle of slightly lower maximum energy (1.31
systemic leakage of the beta radiation emitting radioiso
MeV) and has proven efficacious in human knee radia
tope from the joint being treated and permitting greater
tion synovectomies, it appears that holmium-166 has
control of the particle size of such microspheres. The 10 sufficient penetration for this application. Ho-166 also
radioactive microspheres of the invention are prepared
emits an 80.5 Kev gamma-ray in 6.2% abundance and
from novel microspheres which may be manufactured
thus is imageable by conventional techniques.
and sized before radioactivity is induced providing the
Samarium-153 is produced by neutron capture of
advantage of working only with nonradioactive materi
natural or isotopically enriched samarium-152 with
als during initial production of the microspheres.
15 thermal and resonance neutron cross sections of 210 and
In a first embodiment of the invention, the novel
3,020 bams, respectively. It decays by beta emissions of
radioactive microspheres are comprised of a biodegrad
0.810 MeV (20%), 0.710 MeV (49%), and 0.640 MeV
able glass material selected from the group consisting of
(30%) maximum energies with concomitant ranges of
lithium silicate, lithium aluminosilicate, lithium
about 2.3 mm maximum and 0.8 mm average distance,
aluminoborate, lithium germanate and lithium alumino- 20 respectively. Sm-153 has a physical half-life of 46.27
germanate and containing a beta radiation emitting
hours and produces a highly imageable 103 KeV
radioisotope chemically dissolved in and distributed
gamma ray with an abundance of 29.8%, decaying to
substantially uniformly throughout the glass material,
stable Eu-153.
the radioisotope being samarium-153, holmium-166,
Samarium-153 and holmium-166 are both chemically
erbium-169, dysprosium-165, rhenium-186, rhenium-188 25 compatible and capable of being incorporated into
or yttrium-90. It has been found that lithium silicate,
many types of glass in which no other significant radi
lithium aluminosilicate, lithium aluminoborate, lithium
oactivities induced by neutron bombardment will be
germanate or lithium aluminogermanate biodegradable
present after about one day of decay. Erbium-169, dys
glasses are particularly suitable for the purposes of the
prosium-165, rhenium-186, rhenium-188 (from rheniuminvention since lithium does not become a gamma emit 30
185 and rhenium-187) and yttrium-90 also possess the
ter upon being subjected to neutron irradiation whereas
desired properties rendering them suitable for use as the
sodium, calcium and phosphorus, components of other
radioisotope in this embodiment of the invention.
wise biodegradable glasses, do become gamma emitters
As mentioned, in the first embodiment of the inven
with unacceptably long half-lives upon neutron irradia
tion generally described above, a biodegradable glass
tion or become beta emitters which have undesirably 35
material is selected from the group consisting of lithium
long half-lives or which bond to bone. For example, the
silicate, lithium aluminoborate, lithium aluminosilicate,
composition of the bioactive and partially biodegrad
lithium germanate and lithium aluminogermanate or the
able glass composition known as “Bioglass” is 45%
corresponding potassium glass materials. Such glasses
Si02, 24.5% Na20 , 24.5% CaO and 6% P20 5 (Hench,
Ceramic Implants for Humans, Advanced Ceramic 40 may be doped with samarium oxide (Sm2C>3), holmium
oxide (H o20 3) or oxide of erbium, dysprosium, rhenium
Materials, 1(4):306—324, 1986), and this glass is unsuit
or yttrium in preparing the novel nonradioactive and
able because of the sodium, calcium and phosphorous it
radioactive microspheres of the invention. By way of
contains.
example, such biodegradable glasses so doped may have
Also, while use of the above-noted lithium glass ma
terials is preferred, potassium glasses selected from the 45 the following illustrative compositions by weight per
cent:
group consisting of potassium silicate, potassium alumi
20.1%
L2iO-74.9% S i02-5% Sm20 3
nosilicate, potassium aluminoborate, potassium germa
21.8% Li20-3.9% Al20 3-69.3% Si02-5% Sm20 3
nate and potassium aluminogermanate may also be used
19.7% Li20-13.1% B20 3-62.2% S i02-5% Sm20 3
in the practice of the invention. While potassium does
become a gamma emitter upon being subjected to neu 50 It will be understood that other lithium silicate, lithium
aluminosilicate, lithium aluminoborate, lithium germa
tron irradiation, the radioisotope potassium-42 thus
nate and lithium aluminogermanate glass materials or
produced has an acceptably short half-life of approxithe corresponding potassium glass materials suitably
ately 12 hours. Therefore, when such potassium glass
doped
with samarium, holmium, erbium, dysprosium,
materials are employed, administration of the radioac
tive microspheres containing them is delayed for a suffi 55 rhenium or yttrium may also be used in the practice of
the invention.
cient time to permit the potassium-42 to decay to ac
In a second embodiment of the invention, the novel
ceptable levels.
radioactive microspheres are comprised of a biologi
The above-noted beta radiation emitting radioiso
cally compatible glass material selected from the group
topes are also particularly suitable for use in the present
invention. Samarium-153 (46.3. hr. half-lifej and holmi- 60 consisting of magnesium aluminosilicate and aluminosil
icate glass material and containing a beta radiation emit
um-166 (26.8 hr. half-life) can readily be dissolved in
ting radioisotope chemically dissolved in and distrib
silicate, aluminosilicate or aluminoborate glasses, have
uted substantially uniformly through the glass material,
good activation properties in a nuclear reactor, possess
the radioisotope being samarium-153, holmium-166,
imageable gamma rays, exhibit low toxicity and have
half-lives long enough for distribution of the radioactive 65- erbium-169, dysprosium-165, rhenium-186 or rhenium188. While such glass materials are not biodegradable,
microspheres of the invention containing them.
they are biologically compatible and are useful in the
Holmium-166 is produced by neutron capture on
practice of the invention. Such glass compositions may
100% abundant, stable holmium-165 with thermal neu
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be prepared by doping magnesium aluminosilicate or
aluminosilicate glass materials with oxides of samarium
(S1112O3), holmium (H02O3), erbium (Er2C>3), dys
prosium (Dy203), or rhenium (R e02). Illustrative spe
cific examples of such glass compositions include the
following compositions by weight percent.
20% MgO-21% Al2C>3-52% S i02-7% Sm20 3
40% Y2O3-20% Al2O3-40% S i02
40% Sm2O3-20% Al2O3-40% S i02
20% MgO-21% Al20 3-52% Si02-7% H02O3
20% MgO-21% Al20 3-52% S i02-7% R e0 2
It will be understood that other magnesium aluminosili
cate or aluminosilicate glass materials suitably doped
with samarium, holmium, erbium, dysprosium or rhe
nium may also be used in the practice of the invention.
The microspheres of the present invention may be
prepared from a homogeneous mixture of powders (i.e.
the batch) that is melted to form the desired glass com
position. The exact chemical compounds or raw materi
als used for the batch is not critical so long as they
provide the necessary oxides in the correct proportion
for the melt composition being prepared. For example,
if a samarium doped lithium silicate glass is being made,
then Sm203, Li2C 0 3 and S i02 powders would be used
as the batch raw materials. The purity of each raw
material is typically greater than 99.9%. After either
dry or wet mixing of the powders to achieve a homoge
nous mixture, the mixture may be placed in a platinum
crucible for melting. High purity alumina crucibles can
also be used if at least small amounts of alumina can be
tolerated in the glass being made. The raw materials
must not contain impurities that become radioactive
from neutron irradiation.
The crucibles containing the powdered batch are
then placed in an electric furnace heated to 1500° to
1600° C. depending upon the composition. In this tem
perature range, the batch melts to form a liquid which is
stirred several times to improve its chemical homogene
ity. The melt should remain at 1500° to 1600° C. until all
the solid batch is totally dissolved. This usually requires
2 to 5 hours duration. When melting and stirring is
complete, the crucible is removed from the furnace and
the melt is quickly quenched to a glass by pouring the
melt onto a cold steel plate or into cold clean water.
This procedure breaks the glass into fragments, which
aids and simplifies crushing the glass to a fine powder
(less than 400 mesh). The powder is then sized and
spheridized for use.
The quenched and broken glass is first crushed to
about minus 100 mesh particle size using a mortar and
pestle. The minus 100 mesh material is then ground
using a mechanized mortar and pestle or ball mill until
it passes a 400 mesh sieve. The minus 400 mesh particles
(37 microns in diameter) may be stored in a dry con
tainer until used.
The particles are formed into glass microbeads or
microspheres by introducing the minus 400 mesh parti
cles into a gas/oxygen flame where they are melted and
a spherical liquid droplet is formed by surface tension.
This droplet is rapidly cooled before it touches any
solid object so that its spherical shape is retained in the
solid. Just prior to spheridizing, the minus 400 mesh
powder is rescreened through a 400 mesh sieve to de
stroy any large agglomerates that may have formed
during storage. The minus 400 mesh powder is then
placed in a vibratory feeder located above the gas/oxy
gen burner. The powder is slowly vibrated into a verti
cal glass tube which guides the powder particles di

rectly into the hot flame of the gas/oxygen burner. A
typical rate for feeding the powder to the flame is 5 to
25 grams/hour with the described apparatus. The flame
of the burner is directed into a small metal container
which catches the small glass beads or spheres as they
are expelled from the flame.
After spheridization, the glass spheres are collected
and rescreened with a sonic sifter. For use in the present
invention, the fraction in the range of 3 to 30 microns in
diameter is recovered since this is the desirable size for
use in radiation synovectomy of arthritic joints. After
screening, the microspheres in this size range are exam
ined with an optical microscope and are then washed
with a weak acid (HC1, for example), filtered and
washed several times with reagent grade acetone. The
washed beads or spheres are then heated in a furnace in
air to 500°-600° C. for 2-6 hours to destroy any organic
material therein.
The final step is to examine a representative sample of
the microspheres in the selected size range or fraction in
a scanning electron microscope. The size, range and
shape of the beads or spheres are evaluated, and the
quantity of undersize beads (less than 3 microns in diam
eter) is determined along with the concentration of
non-spherical particles. The composition of the beads
can be checked by energy dispersive x-ray analysis to
confirm that the composition is correct and that there is
an absence of chemical contamination.
The glass microspheres are then ready for activation
by being subjected to an effective amount of neutron
irradiation which will produce a beta radiation emitting
radioisotope of samarium-153, holmium-166, erbium169, dysprosium-165, rhenium-186, rhenium-188 or yt
trium-90, the amount depending upon the particular
isotope of these elements that has been chemically dis
solved and uniformly distributed throughout the glass
material. The resulting radioactive microspheres of the
invention have beta radiation emitting energies highly
suitable for radiation synovectomy of arthritic joints
and also provide gamma ray emissions suitable for nu
clear medicine imaging devices.
In accordance with the invention, the radioactive
microspheres prepared as described may be adminis
tered to the afflicted joints by intra-articular injection or
by other suitable means of administration. The micro
spheres are believed to be chemically durable in joint
fluids and mechanically contained within the joint cav
ity. Moreover, upon administration, they become dis
tributed reasonably uniformly along the synovial mem
brane and emit beta radiation of sufficient range to fully
or substantially fully irradiate the thickness of the mem
brane without giving significant dosage to more distant
joint structures. Also, inasmuch as the thickness of the
diseased membrane varies in different joints, the present
invention makes possible the preparation of micro
spheres doped with a different energy beta emitter for a
finger joint than for a knee, for example.
Further, the present invention provides smooth mi
crospheres which constitute a preferred shape over
irregular, jagged particles with sharp edges and corners
for the purpose of radiation synovectomy of arthritic
joints. The smooth surface of a sphere should be more
tissue compatible and less irritating than other shapes.
The smooth shape of the microspheres of the invention
should also cause less friction, mechanical wear and
inflammation in a joint with moving parts than irregu
larly shaped particles. Heretofore, radioactive micro
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9
spheres of the type provided by the present invention
have not been available nor have glass microspheres of
this type been injected into arthritic joints of huriians or
animals.
While, as indicated, the microspheres of the present 5
invention may be of various sizes, it is preferred for
radiation synovectomy of arthritic joints that the microspheres have a diameter within the range of about 3 to
30 micrometers (microns).
To localize the desired radiation to the affected joint, 10
the radioactive element is chemically dissolved in a host
glass material which is insoluble in the body. The es
cape or leakage of the radioactive material from the
joint has been a major problem with other types of
materials (e.g. colloids) previously used in this type of 15
radiation therapy and an insoluble glass should prevent
any leakage since the radioactive material cannot es
cape from insoluble glass microspheres. Also, for use in
human joints, there is a perceived advantage to using
glass beads or microspheres which gradually dissolve 20
after they are no longer radioactive, i.e. which are bio
degradable. Accordingly, in accordance with the pres
ent invention, it is preferred to employ the biodegrad
able glass microspheres which are initially insoluble
25
during the period of time the bead is radioactive (i.e.
few weeks) and which then gradually starts to dissolve
and eventually disappear.
Biodegradable glass microspheres having such de
sired characteristics may be prepared through another 30
aspect of the present invention by treating the abovedescribed biodegradable lithium silicate, lithium alumi
nosilicate, lithium aluminoborate, lithium germanate,
lithium aluminogermanate or corresponding potassium
glass microspheres in such a way as to form an insoluble 35
or sparingly soluble coating on its outer surface. This
can be done by washing such glasses in common acids
such as hydrochloric acid, nitric acid or sulfuric acid
and thereby replace the lithium or potassium ions on the
outer surface with protons or H3O+. The results of this 40
dealkalization process is to produce a thin layer (skin)
on the surface of the glass beads or microspheres whose
solubility is less than than of the underlying glass. A
glass bead with such a dealkalized surface initially dis
solves slowly until the more durable outer surface layer 45
is dissolved, and then starts to dissolve faster as the less
durable, underlying glass is exposed to the surrounding
media.
Thus, washing glass microspheres of the invention in
common acids is an exemplary and practical means of 50
achieving the desired dissolution characteristics re
quired for radioactive, biodegradable glass micro
spheres for use in human joints. It will be understood by.
those skilled in the art that various factors are important
to the dissolution characteristics of the dealkalized sur 55
face or skin. These are: (1) the starting glass composi
tion, especially the amount of alkali ion (i.e. lithium or
potassium) present; (2) concentration and type of acid
employed; (3) temperature of the acid; (4) time of acid
treatment; and (5) heat treatment of dealkalized surface 60
after acid wash. It will also be understood by those
skilled in the art that in addition to acid washing, other
procedures such as heating a glass in various gases such
as SO2 and F2 can be used to produce a more chemically
durable dealkalized skin on the lithium and potassium 65
glasses described above.
The following examples further illustrate the inven
tion.

EXAMPLE 1
31 rabbits were injected with about 5 mg each of
non-radioactive glass microspheres (20-30 microns in
size) having the composition by weight: 40% Y2O320% Al2C>3-40% SiC>2. The injections were made in the
left stifles (knee) using Angiovist 370 contrast medium
(diatrizoate meglumine and diatrizoate sodium; Berlex
Laboratories, Incorporated) as a suspending medium,
with a control injection of Angiovist in the right stifle.
The rabbits showed no ill effects whatsoever over peri
ods langing from 48 hours to three months. Upon sacri
fice at intervals of 2 to 90 days, the stifles were all dis
sected and slides prepared of various joint tissues. Ex
amination of the slides revealed microspheres only
along the synovium with no spheres apparent in the
underlying fat tissue or lymph nodes, and no mechani
cal abrasion or damage to the cartilage or other joint
structures.
EXAMPLE 2
FIGS. 1 and 2 show the dissolution (weight loss in
mg/cm2) of two different glass compositions as shown
thereon in deionized water at 37° C. as a function of
time. The straight lines labeled 3 mos. and 6 mos. desig
nate the dissolution needed for a 30 micron bead or
sphere to dissolve in 3 and 6 months, respectively. In
addition to untreated specimens (control), each figure
also shows the dissolution of specimens of each glass
composition washed in IN HC1 for 4 hours at either 25°
or 50° C.
The effectiveness of the acid wash in reducing the
dissolution at short times is clearly evident in FIG. 1 for
the specimen washed in HC1 at 25° C. In contrast to the
unwashed control which showed an immediate weight
loss, the sample washed in acid at 25° C. did not show
any detectable weight loss for more than one week in
deionized water. After about one week, the sample then
began to dissolve as desired. Similar results are given in
FIG. 2, except that acid washing at 50° C. was more
effective for this glass because of its different composi
tion.
These studies show that acid washing produces an
insoluble surface skin which yields the dissolution char
acteristics needed for radioactive, biodegradable glass
microspheres for use in human joints.
EXAMPLE 3
'

A. Sample Preparation

The glass compositions in the following table were
prepared from reagent grade chemicals. Batches yield
ing 50 grams of glass were melted in platinum crucibles
in an electric furnace at approximately 1,350° C. The
melt was held at 1,350° C. for 1 to 2 h for fining and
homogenization and then cast into steel molds to form
bars measuring approximately 1X 1X 8 cm which were
annealed at 500° C. for 30 min. and then slowly cooled
to room temperature. Slabs approximately 0.2 x 1X 1
cm were cut from the bars and ground to rectangular
shape using 180 grit silicon carbide paper.
C O M PO SITIO N O F G LA SSES
_____ Batch Composition (W eight %)______
Glass________SiO?
LnO
AbO.t
SM 2O 3
LSI

74.9

20.1

0.0

5.0
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D. Sem Analysis

Selected microspheres and slabs were, mounted on a
Batch Composition (W eight %)
steel cylinder for SEM analysis. The slabs were broken
Glass
S i0 2
L i20
A120 3
SM 20 3
5 and one piece was mounted to observe the corroded
LS3
69.3
21.8
3.9
5.0
surface and the other to observe the fresh fracture sur
face. The mounted slabs and microspheres were vapor
coated
with palladium.
A portion of the LSI glass was broken and ground to
Because the as-cut slabs had a very rough surface,
—200 mesh and wet milled for 6 h with methanol. The
10 polished slabs were used to see the effects of surface
powder was then dried and screened through a 325
treatments. The surface of slabs of each glass was pol
mesh sieve. The —325 mesh glass powder was slowly
ished to 1 micron using silicon carbide polishing paper
fed into an oxygen/propane flame where surface ten
and finally one micron AI2O3. These slabs were left
sion caused the molten particles to become spheres.
untreated, treated in acid, or treated in acid followed by
15 heat treatment (LSI: 350° C. for 30 minutes, LS3: 400°
B. Surface Treatments
C. for 45 minutes). These samples were examined by
1. Sulfur Dioxide Gas
SEM to determine if there was any change in the sur
The glass slabs were placed in a tube furnace at either
face due to washing in acid or washing in acid followed
400° or 500° C. SO2 gas was bubbled through water at
by heat treatment.
25° C. at an approximate rate of one bubble per second 20
E. Results and Conclusions
before flowing through the furnace. The treatment
times were 90 min. at 400° C. and 15 or 45 min. at 500°
LSI glass which contains 74.9% SiCb, 20.1% Li20,
C. After removal from the furnace, the slabs were and 5.0% Sm203 (weight %) is well suited for micro
cooled, rinsed in distilled water to remove any lithium
spheres that could be irradiated to treat rheumatoid
sulphate formed on the surface, and dried in an oven at 25 arthritis. Acid washing followed by heating LSI re
100° C.
duced the dissolution to zero. Glasses acid washed and
2. Washing in HC1
heated at 400° C. remained insoluble after 6 months.
The glass was placed in a 0.1N HC1 solution in a
LSI glass acid washed then heated for 10 min. at 350° C.
remained insoluble for 4 weeks and then began to dis
beaker, magnetically stirred, rinsed in distilled water,
and dried in air at 100° C. Initially, the effect of acid 30 solve at approximately half of the rate calculated for a
30 micron sphere to dissolve in 6 months. If this glass
washing on the glasses for 2, 4, 6 or 8 h at 25° C., 50° C.,
continued to dissolve at this rate, then a 30 micron
or 75° C. was examined. The time and temperature
sphere treated in this way should be totally dissolved in
which gave the longest delay before dissolution com
12 months. Acid washing followed by heat tretment of
menced for LSI was 4 h at 25° C. an for LS3 was 4 h at
50° C. These times and temperatures were used in subse 35 LSI glass for 10 min. for 350° C. appears to create a
temporarily insoluble surface layer which should pre
quent heat treatments.
vent the release of radioactive Sm-153.
3. Washing in HC1 Followed by Heat Treatment
SEM photographs of polished LS3 glass shows that
After washing in 0.1 N HC1 acid, the glass slabs were
acid washing followed by heating causes the surface to
heated on a steel plate in a furnace to 350° or 400° C. At
350° C., the slabs were heated for 10 or 30 min. and at 40 crack. This is probably due to a difference in thermal
expansion between the bulk glass and the dealkalyzed
400° C., the slabs were heated for 10, 30, 45, 60, or 90
layer. Acid washed then heated LS3 glasses began to
min. Microspheres of LSI were heated at 350° C. for 30
dissolve immediately confirming no protective layer
min.
was created. In LS3 glass acid washed then heated at
45 400° C., the initial dissolution rate paralleled the acid
C. Chemical Dissolution Measurements
washed glass. After a few weeks, the dissolution de
After surface treatments, the glass slabs were
creased to almost zero, suggesting the corrosion process
weighed and their exact dimensions measured before
caused a protective layer to develop.
placing them in polyethylene bottles containing 125 mL
Washing LSI and LS3 glass in 0.IN HC1 delays the
of distilled water (pH =7). The bottles were placed in 50 dissolution of LS3 for 5 days and of LSI for 7 days.
an oven at 37° C., which is the temperature of the
Dissolution then begins at approximately the same rate
human body. The weight change of each slab was mea
as the untreated glass.
sured periodically by removing the slab from the bottle,
Exposure to hot sulfur dioxide gas decreases the dis
drying it in an oven at 100° C., and weighing.
solution of LSI glass in water at 37° C. but does not
The average dissolution, D, of each sample was cal 55 significantly affect the dissolution of LS3. No delay in
culated from the equation
dissolution occurred for either glass. Decreasing the
temperature of the S 0 2 treatment may facilitate the
D = ( W 0- W )/A
dealkalyzing reactions of the SO2 and improve the
chemical durability of the surface.
where W0 was the initial weight of the original slab, 60
SEM photographs confirm that the acid washed then
W was the current weight of the slab, and A was the
heated slabs of LSI which had a zero dissolution rate
surface area of the slab. The dissolution was plotted
show no effect of corrosion, while the acid washed and
against time.
untreated slabs showed cracking after two weeks in
Approximately 20 mg of microspheres made from the
water.
LSI glass were placed in polyethylene bottles contain 65
EXAMPLE 4
ing 25 mL'of distilled water and placed in an oven at 37°
C. The microspheres were removed after 3 weeks for
. About 10 mg. of non-biodegradable glass micro
SEM analysis.
spheres (10-20 microns in size) having the composition
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by weight: 20% MgO-21% Al20 3-52% S i02-7%
urn-169, dysprosium-165, rhenium-186, rhenium-188
Sm203, were irradiated 10 minutes in a neutron flux of
and yttrium-90, treating said doped glass material with
4E13/square cm/sec to make about 300 microcuries of
an acid wash to produce a thin layer on the surface of
Sm-153. The microspheres were irradiated in sealed,
the glass material and heat treating the glass material to
high density polyethylene vials having a volume of 5 improve the chemical durability of the glass material by
slightly more than 1 cc and drawn into 1 cc tuberculin
rendering the solubility of said layer lower than that of
syringes using Angiovist contrast medium as a suspend
the underlying glass material.
ing agent and injected into the stifles of healthy rabbits.
2. A method as set forth in claim 1 wherein said heat
Serial imaging was performed to ascertain leakage.
treating step is carried out in the presence of S 0 2 gas.
Significant leakage was observed down the leg of the 10 3. A method as set forth in claim 1 wherein said acid
first four rabbits, but this appeared to occur due to
wash is selected from the group consisting of hydro
leakage out of the injection puncture and possible tear
chloric acid, sulfuric acid and nitric acid.
in the joint capsule. A fifth rabbit injected through the
4. A method as set forth in claim 1 wherein said glass
cartilage in the front of the knee (i.e. through a thicker,
material is lithium silicate and said radioisotope is
self-sealing portion of the joint) exhibited no leakage. 15 samarium-153.
In view of the above, it will be seen that the several
5. A method as set forth in claim 1 wherefn said glass
objects of the invention are achieved and other advanta
material is lithium aluminosilicate and said radioisotope
geous results attained.
is samarium-153.
As various changes could be made in the above prod
6. A method as set forth in claim 1 wherein said glass
ucts and methods without departing from the scope of 20 material is lithium aluminoborate and said radiosotope is
the invention, it is intended that all matter contained in
samarium-153.
the above description or shown in the accompanying
7. A method as set forth in claim 1 wherein said glass
drawings shall be interpreted as illustrative and not in a
material is lithium silicate and said radioisotope is hol
limiting sense.
mium-166.
What is claimed is:
25
8. A method as set forth in claim 1 wherein said glass
1.
A method for preparing nonradioactive micro material is lithium aluminosilicate and said radioisotope
spheres adapted for radiation synovectomy of arthritic
is holmium-166.
joints in a mammal comprising forming said micro9. A method as set forth in claim 1 wherein said glass
spheres by doping microspheres formed of a biodegrad
material is lithium aluminoborate and said radioisotope
able glass material selected from the group consisting of 30 is holmium-166.
lithium silicate, lithium aluminosilicate, lithium
10. A method as set forth in claim 1 wherein said glass
aluminoborate, lithium germanate, lithium aluminogermaterial is magnesium aluminosilicate and said radioiso
manate, potassium silicate, potassium aluminosilicate,
tope is samarium-153.
potassium aluminoborate, potassium germanate and
11. A method as set forth in claim 1 wherein said glass
potassium aluminogermanate with an isotope selected 35 material is aluminosilicate and said radioisotope is
from the group consisting of samarium, holmium, er
samarium-153.
bium, dysprosium, rhenium and yttrium so that said
12. A method as set forth in claim 1 wherein said glass
isotope is chemically dissolved in and distributed sub
material is aluminosilicate and said radioisotope is yttristantially uniformly throughout said microspheres ma
um-90.
terial and which isotope, upon being subjected to an 40
13. A method as set forth in claim 1 wherein said
effective amount of neutron irradiation, will produce a
microsphere has a diameter in the range of about 3 to
beta radiation emitting radioisotope selected from the
about 30 micrometers.
group consisting of samarium-153, holmium-166, erbi* * * * *
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